Double ERC success for DKFZ researchers
With its Proof of Concept (PoC) grants, the European Research Council (ERC) supports scientists in further developing the economic potential of their research results. Two scientists from the German Cancer Research Center (DKFZ) have now been selected for this prestigious funding: Hellmut Augustin is developing novel mouse tumor models that will ensure better transferability of results while reducing the number of animals used in experiments. Michael Platten plans to further develop an AI-driven classifier to accelerate the complex production of therapeutic T cells for immunotherapy.
What is special about the ERC's “Proof of Concept” grants is that only those who already receive ERC funding can apply for this grant. The Research Council wants to enable scientists to test and explore possible applications for the research results they have achieved in an ERC-funded project.
Cancer is extremely complex and affects the entire body, meaning that many questions can only be investigated in living organisms. Mice are used almost exclusively for this purpose. Researchers today use various techniques to study cancer in rodents. For example, tumor cells are transferred to the animal or cancer is induced through genetic engineering. However, the various approaches have disadvantages that often mean that the situation in humans is not adequately replicated. With the SpheroMouse project, Hellmut Augustin, head of the Department of Vascular Oncology and Metastasis at the DKFZ and the Department of Vascular Biology and Tumor Angiogenesis at the University Medical Center Mannheim, aims to improve the significance of this research. His goal is to better adapt the results from animal experiments to the situation in humans, thereby increasing the scientific quality and transferability of preclinical mouse tumor research.
His approach is based on transplanting tiny fragments of established tumors, barely a tenth of a millimeter in size, obtained from genetically modified mouse models. This procedure enables scientific findings with greater significance and significantly improved transferability to humans than the cell line tumor models that have been predominantly used to date. The fragments can be molecularly standardized, stored in biobanks, and conveniently shipped, making them available to researchers worldwide. At the same time, the project also makes a significant contribution to animal welfare, as more reproducible results in standardized models mean that fewer animals need to be used for experiments.
Personalized T-cell therapies are considered promising new treatment options for various types of cancer. The therapeutic T cells are first equipped in the laboratory with special sensor proteins, the “T-cell receptors,” which recognize the individual tumor. However, identifying the appropriate T-cell receptors is a particularly time-consuming step in the production of personalized therapeutic T cells.